0001493152-18-005767.txt : 20180425 0001493152-18-005767.hdr.sgml : 20180425 20180425164428 ACCESSION NUMBER: 0001493152-18-005767 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20180425 DATE AS OF CHANGE: 20180425 EFFECTIVENESS DATE: 20180425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEMISPHERX BIOPHARMA INC CENTRAL INDEX KEY: 0000946644 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 520845822 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-310992 FILM NUMBER: 18774860 BUSINESS ADDRESS: STREET 1: 860 N. ORANGE AVENUE STREET 2: SUITE B CITY: ORLANDO STATE: FL ZIP: 32801 BUSINESS PHONE: 407-271-8516 MAIL ADDRESS: STREET 1: 860 N. ORANGE AVENUE STREET 2: SUITE B CITY: ORLANDO STATE: FL ZIP: 32801 D 1 primary_doc.xml X0708 D LIVE 0000946644 HEMISPHERX BIOPHARMA INC 860 N. ORANGE AVENUE SUITE B ORLANDO FL FLORIDA 32801 215-988-0080 DELAWARE None None Corporation true Thomas K Equels 860 N. ORANGE AVE SUITE B ORLANDO FL FLORIDA 32801 Executive Officer Director Adam Pascale 600 Main Street Suite 2 Riverton NJ NEW JERSEY 08077 Executive Officer David Strayer 600 Main Street Suite 2 Riverton NJ NEW JERSEY 08077 Executive Officer Wayne Springate 600 Main Street Suite 2 Riverton NJ NEW JERSEY 08077 Executive Officer William Mitchell Vanderbilt Medical Center North 21st & Garland Nashville, TN TENNESSEE 37232 Director Peter W Rodino 27499 Riverview Center Blvd. Suite 124 Bonita Springs, FL FLORIDA 34134 Executive Officer Stewart Appelrouth 999 Ponce de Leon Blvd. Suite 625 Coral Gables, FL FLORIDA 33134 Director Pharmaceuticals Decline to Disclose 06b false 2018-04-24 false true false 975 Maxim Group LLC 120708 None None 405 LEXINGTON AVE NEW YORK NY NEW YORK 10174 CA CALIFORNIA FL FLORIDA IL ILLINOIS NJ NEW JERSEY NY NEW YORK PA PENNSYLVANIA TX TEXAS false 25740 25740 0 Warrants herein sold to investors when investors purchased registered shares. $01 of the total $0.39 per share purchase price of securities allocated to purchase of private warrants referred to herein. false 3 1802 true 0 Represents same percentage of total placement agent fees received for combination of public share and private warrant offering as set forth in item 13 above. 0 true false HEMISPHERX BIOPHARMA INC Thomas K. Equels Thomas K. Equels President 2017-04-25